Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Pivotal Phase 2 trial data for tagraxofusp in BPDCN

Naveen Pemmaraju • 15 Jun 2019
EHA 2019
Tagraxofusp

Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, explains the efficacy and safety results of the pivotal Phase II trial (NCT02113982) of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm (BPDCN). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Naveen Pemmaraju

1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
1:15
Exploring the evolving treatment landscape of myelofibrosis
Naveen Pemmaraju • 3 Jun 2023
The content of VJHemOnc is intended for healthcare professionals